Miltuximab® for Therapeutic & Imaging Applications.
We are examining multiple mechanisms of action including:
- Radio immunotherapy
- Bispecific antibodies
- Immune cell engagement and activation
We have now completed a first in-human trial using Miltuximab®, our anti-GPC-1 monoclonal antibody (ANZCTR registry).
The trial dosed 12 patients and no drug-related adverse events were observed.
Glytuzumab® refers to the humanized version of Miltuximab® and also targets human GPC-1. The Glytuzumab® program is currently undergoing Lead Optimisation and Lead Selection stages. Several humanized leads have been generated with similar binding affinities as that of the parent molecule Miltuximab®. The final Glytuzumab® lead selected will be taken forward from cell line development through to large scale GMP production for future clinical trials.
Achievements
2019
First-In-Human Clinical trial of Miltuximab® conjugated to 67Gallium for imaging met primary endpoint of safety in all patients
Preclinical work now completed for upcoming Phase I Clinical trial in GPC-1 expressing solid tumours. This will use Miltuximab® labelled with either 89Zirconium for imaging or 177Lutetium for therapy
Antibody composition of matter patents granted EU and US
2018
Completion of accrual for clinical study of Miltuximab® in prostate, bladder and pancreatic cancers
2017
The second stage of pioneering MILGa clinical trial of Miltuximab®
2016
Commenced First-In-Human trial of Miltuximab®
2015 Eureka Prize
Excellence in Interdisciplinary Scientific Research
Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.
Suite 2, Ground Floor, 75 Talavera Road, Macquarie Park, NSW 2113, Australia
Phone
International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here
Email
info@glytherix.com
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.
Headquarters of Glytherix
